Evolution Marketing Research, the next generation pharmaceutical marketing research and consulting company, announced that it has proactively restructured in order to better take advantage of the evolving global pharmaceutical marketplace in coming years. As a keystone of this restructuring, the company has instituted a new strategy called "Intelligent Efficiency." This strategy is intended to allow the company to compete effectively in this new market environment with a streamlined organizational structure."Over the past decade, the pharmaceutical marketing research industry has known nothing but solid, often dramatic, growth. The pharmaceutical industry, however, has changed and the new definition of success in these trying economic times is stability rather than growth, in large part due to shrinking pharma marketing research budgets," said company Principal James Cummings.Evolution's founding principals look forward to a more stable market environment in the year to come which will allow for the development of new relationships in the biopharma industry. "By every definition of the term, Evolution had a stable year and is poised for success in the future," explains Daniel Slawe, Chief Operating Officer. "The restructuring of the company under our new Intelligent Efficiency program will allow us to continue to provide best-in-class service to our clients."An important part of this drive will be the development of new and innovative research methodologies and products. "Evolution is constantly in the process of creating new key products, several of which will be launching over the course of this year [2012]," said Principal Dr. James Heasley. "This is in keeping with our corporate mission of continuing to innovate and lead in an industry that is always seeking to enhance efficiencies." In 2011, the company introduced a range of innovative methodologies such as the well-received PreSIM(SM) qualitative conjoint method and its ActiveInsight(TM) custom omnibus study.Through the Intelligent Efficiency initiative, Evolution is committed to introduction of new and original methodologies geared toward aiding clients to make the most of their resources.
Subscribe to:
Post Comments (Atom)
Superhit News
-
US health regulator USFDA has issued a warning letter to German drug firm Fresenius Kabi AG for lapses at its drug manufacturing fac...
-
Goods and Service Tax (GST) is high on the agenda for the new government and its rollout is a priority. GST will benefit the Indian pharma...
-
Rib-X Pharmaceuticals, Inc. announced today the signature of an exclusive worldwide research collaboration agreement and option for license ...
-
Physiomics: Reports difficult trading but highlights growing interest from big pharmaceutical groupsPhysiomics ( LON:PYC ) said that trading conditions were difficult in the six months ended 31 December 2010, but it believes it is in a be...
-
Hindusthan National Glass and Industries Ltd is expected to finalize a strategic overseas acquisition in the pharmaceuticals space in the n...
-
The Minister of State (Health and Family Welfare), Sh Ashwini Kumar Choubey through a written reply in the Lok Sabha informed about th...
-
The government is hoping to see the implementation of the track and trace system for domestic and export supply chain in another one y...
-
India's Central Drugs Standard Control Organization (CDSCO) has suspended the manufacturing of eye drops at the Chennai-based firm after...
-
Diclofenac injection is a painkiller which is manufactured by Themis Medicare Ltd and marketed by Novartis India under the brand name ...
-
Amylin Pharmaceuticals, Inc. AMLN +16.15% and Alkermes plc ALKS +4.61% today announced that the U.S. Food and Drug Administration (FDA) has ...
No comments:
Post a Comment